SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 6, 2010, Pages 2044-2047

  Desai, Dhimant ^a   Salli, Ugur ^a   Vrana, Kent E ^a   Amin, Shantu ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Histone deacetylase inhibitors; Selenium analogs of SAHA; Synthesis

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; SELENIUM DERIVATIVE; SELSA 1; SELSA 2; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; COMPARATIVE STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; IC 50;

HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS;

EID: 77649193260     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.068     Document Type: Article

References (53)

1. Alam H.B., and Rhee P. Surg. Clin. North. Am. 87 (2007) 55
2. Bouchain G., Leit S., Frechette S., Khalil E.A., Lavoie R., Moradei O., Woo S.H., Fournel M., Yan P.T., Kalita A., Trachy-Bourget M.C., Beaulieu C., Li Z., Robert M.F., MacLeod A.R., Besterman J.M., and Delorme D. J. Med. Chem. 46 (2003) 820
3. Grunstein M. Nature 389 (1997) 349
4. Bolden J.E., Peart M.J., and Johnstone R.W. Nat. Rev. Drug Disc. 5 (2006) 769
5. Glaser K.B. Biochem. Pharmacol. 74 (2007) 659
6. Archer S.Y., and Hodin R.A. Curr. Opin. Genet. Dev. 9 (1999) 171
7. Kouzarides T. Curr. Opin. Genet. Dev. 9 (1999) 40
8. Hassig C.A., and Schreiber S.L. Curr. Opin. Chem. Biol. 1 (1997) 300
9. Suzuki T., Kouketsu A., Matsuura A., Kohara A., Ninomiya S., Kohda K., and Miyata N. Bioorg. Med. Chem. Lett. 14 (2004) 3313
10. Johnstone R.W. Nat. Rev. Drug Disc. 1 (2002) 287
11. Minucci S., and Pelicci P.G. Nat. Rev. Cancer 6 (2006) 38
12. Catley L., Weisberg E., Tai Y.T., Atadja P., Remiszewski S., Hideshima T., Mitsiades N., Shringarpure R., LeBlanc R., Chauhan D., Munshi N.C., Schlossman R., Richardson P., Griffin J., and Anderson K.C. Blood 102 (2003) 2615
13. Chen H., Alam H.B., Querol R.I., Rhee P., Li Y., and Koustova E. J. Trauma 60 (2006) 701
14. Curtin M.L., Garland R.B., Heyman H.R., Frey R.R., Michaelides M.R., Li J., Pease L.J., Glaser K.B., Marcotte P.A., and Davidsen S.K. Bioorg. Med. Chem. Lett. 12 (2002) 2919
15. Drummond D.C., Noble C.O., Kirpotin D.B., Guo Z., Scott G.K., and Benz C.C. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 495
16. Kouraklis G., and Theocharis S. Curr. Med. Chem. Anticancer Agents 2 (2002) 477
17. Pandolfi P.P. Cancer Chemother. Pharmacol. 1 (2001) S17
18. Plumb J.A., Steele N., Finn P.W., and Brown R. Biochem. Soc. Trans. 32 (2004) 1095
19. Remiszewski S.W. Curr. Opin. Drug Discovery Dev. 5 (2002) 487
20. Remiszewski S.W., Sambucetti L.C., Atadja P., Bair K.W., Cornell W.D., Green M.A., Howell K.L., Jung M., Kwon P., Trogani N., and Walker H. J. Med. Chem. 45 (2002) 753
21. Yoshida M., Horinouchi S., and Beppu T. BioEssays 17 (1995) 423
22. Yoshida M., Kijima M., Akita M., and Beppu T. J. Biol. Chem. 265 (1990) 17174
23. Yoshida M., Furumai R., Nishiyama M., Komatsu Y., Nishino N., and Horinouchi S. Cancer Chemother. Pharmacol. 1 (2001) S20
24. Hoshikawa Y., Kwon H.J., Yoshida M., Horinouchi S., and Beppu T. Exp. Cell Res. 214 (1994) 189
25. Donadelli M., Costanzo C., Faggioli L., Scupoli M.T., Moore P.S., Bassi C., Scarpa A., and Palmieri M. Mol. Carcinog. 38 (2003) 59
26. Leoni F., Zaliani A., Bertolini G., Porro G., Pagani P., Pozzi P., Dona G., Fossati G., Sozzani S., Azam T., Bufler P., Fantuzzi G., Goncharov I., Kim S.H., Pomerantz B.J., Reznikov L.L., Siegmund B., Dinarello C.A., and Mascagni P. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 2995
27. Cohen L.A., Amin S., Marks P.A., Rifkind R.A., Desai D., and Richon V.M. Anticancer Res. 19 (1999) 4999
28. Desai D., Das A., Cohen L., El-Bayoumy K., and Amin S. Anticancer Res. 23 (2003) 499
29. Zhang C., Richon V., Ni X., Talpur R., and Duvic M. J. Invest. Dermatol. 125 (2005) 1045
30. Marks P.A. Oncogene 26 (2007) 1351
31. Belien A., De Schepper S., Floren W., Janssens B., Marien A., King P., Van Dun J., Andries L., Voeten J., Bijnens L., Janicot M., and Arts J. Mol. Cancer Ther. 5 (2006) 2317
32. Jaboin J., Wild J., Hamidi H., Khanna C., Kim C.J., Robey R., Bates S.E., and Thiele C.J. Cancer Res. 62 (2002) 6108
33. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., and Nakanishi O. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 4592
34. Prakash S., Foster B.J., Meyer M., Wozniak A., Heilbrun L.K., Flaherty L., Zalupski M., Radulovic L., Valdivieso M., and LoRusso P.M. Invest. New Drugs 19 (2001) 1
35. Acharya M.R., Sparreboom A., Venitz J., and Figg W.D. Mol. Pharmacol. 68 (2005) 917
36. Kijima M., Yoshida M., Sugita K., Horinouchi S., and Beppu T. J. Biol. Chem. 268 (1993) 22429
37. Kosugi H., Towatari M., Hatano S., Kitamura K., Kiyoi H., Kinoshita T., Tanimoto M., Murate T., Kawashima K., Saito H., and Naoe T. Leukemia 13 (1999) 1316
38. Komatsu Y., Tomizaki K.Y., Tsukamoto M., Kato T., Nishino N., Sato S., Yamori T., Tsuruo T., Furumai R., Yoshida M., Horinouchi S., and Hayashi H. Cancer Res. 61 (2001) 4459
39. Piekarz R., and Bates S. Curr. Pharm. Des. 10 (2004) 2289
40. Kwon H.J., Kim M.S., Kim M.J., Nakajima H., and Kim K.W. Int. J. Cancer 97 (2002) 290
41. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., Lin T.S., Liu S., Sklenar A.R., Davis M.E., Lucas D.M., Fischer B., Shank R., Tejaswi S.L., Binkley P., Wright J., Chan K.K., and Grever M.R. Blood 105 (2005) 959
42. Marshall J.L., Rizvi N., Kauh J., Dahut W., Figuera M., Kang M.H., Figg W.D., Wainer I., Chaissang C., Li M.Z., and Hawkins M.J. J. Exp. Ther. Oncol. 2 (2002) 325
43. Yi T., Baek J.H., Kim H.J., Choi M.H., Seo S.B., Ryoo H.M., Kim G.S., and Woo K.M. Exp. Mol. Med. 39 (2007) 213
44. Vigushin D.M., and Coombes R.C. Anticancer Drugs 13 (2002) 1
45. Furumai R., Matsuyama A., Kobashi N., Lee K.H., Nishiyama M., Nakajima H., Tanaka A., Komatsu Y., Nishino N., Yoshida M., and Horinouchi S. Cancer Res. 62 (2002) 4916
46. 3 using a Bruker 500 MHz instrument. The chemical shifts are reported in ppm downfield from TMS. MS were run on 4000 Q trap hybrid triple quadrupole/linear ion trap instrument (Applied Biosystems/MDS Sciex) at the proteomic facility of the Penn State Hershey Cancer Institute, College of Medicine, Hershey, PA. High-resolution MS were determined at the Instrument Center, University of Buffalo, Buffalo, NY. Thin-layer chromatography (TLC) was performed on aluminum-supported, pre-coated silica gel plates (EM Industries, Gibbstown, NJ). All starting materials and reagents were obtained from Aldrich Chemical Co. (Milwaukee, WI) and used without further purification.
47. 1H NMR δ 1.35 (q, 2H, J = 6.7 Hz), 1.57 (q, 2H, J = 7.0 Hz), 1.80 (q, 2H, J = 7.5 Hz), 1.95 (q, 2H, J = 7.0 Hz), 2.41 (t, 2H, J = 7.5 Hz), 3.46 (t, 2H, CH2-Br, J = 7.0 Hz), 7.11 (br s, 1H, NH), 7.14 (t, 1H, aromatic, J = 7.5 Hz), 7.35 (t, 2H, aromatic, J = 7.5 Hz), 7.54 (d, 2H, aromatic, J = 8.0 Hz).
48. 2, 541.0867).
49. 2OSe, 297.0501).
50. Jacob L.A., Matos B., Mostafa C., Rodriguez J., and Tillotson J.K. Molecules 9 (2004) 622
51. 50 of the inhibitor compounds was determined by performing HDAC assay with increasing concentrations (1, 3.3, 10, 33, 100 and 333 nM) of the inhibitor compounds (TSA, SAHA and SelSA-2) under the same conditions.
52. Huang Y., Tan M., Gosink M., Wang K.K., and Sun Y. Cancer Res. 62 (2002) 2913
53. Statistical analysis: Data were combined from two separate HDAC assay experiments and analyzed. Statistical analysis was performed using a standard one-way ANOVA followed by Student Newman-Keuls post-hoc ANOVA test. Differences with p <0.05 were considered significant.